AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PYC THERAPEUTICS LTD

2.250

-0.010-0.44%

Volume:1.77M

Turnover:4.01M

Market Cap:2.21B

PE:-38.07

High:2.350

Open:2.340

Low:2.230

Close:2.260

52wk High:2.620

52wk Low:0.865

Shares:983.26M

Float Shares:348.08M

Volume Ratio:0.51

T/O Rate:0.51%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.059

EPS(LYR):-0.059

ROE:-10.14%

ROA:-8.05%

PB:3.19

PE(LYR):-38.07

Loading ...

Overview Company News Filings

PYC Therapeutics Says First Patient Dosed in Open-Label Extension of Drug Candidate Study in Polycystic Kidney Disease

MT Newswires Live

ASX Biggest Gainers

MT Newswires Live

Why PYC Therapeutics (ASX:PYC) Is Up 10.5% After Narrowing Its Full-Year Net Loss

Simply Wall St.

PYC Therapeutics (ASX:PYC) Shares Chase Revenue Growth Despite Deep Losses

Simply Wall St.

ASX Biggest Losers

MT Newswires Live

ASX Biggest Gainers

MT Newswires Live

PYC Therapeutics Secures Approval for Higher Dosage in Phase 1b Multiple Ascending Dose Study in Polycystic Kidney Disease

MT Newswires Live

PYC Therapeutics Says ADOA Patients Show Sustained Visual Acuity, Retinal Stress Improvements in Drug Candidate Trials

MT Newswires Live

What PYC Therapeutics (ASX:PYC)'s CFO Appointment of Biotech Finance Veteran Means For Shareholders

Simply Wall St.

PYC Therapeutics (ASX:PYC) Names New CFO As Investors Weigh A Pricey Valuation

Simply Wall St.

Will PYC Therapeutics’ New CFO Shift Its Capital-Market Ambitions Up a Gear (ASX:PYC)?

Simply Wall St.

PYC Therapeutics Announces Grant of Patents by the US Patent Office

PYC Therapeutics Says US Patent Office Grants Composition of Matter Patents for Three Drug Candidates

MT Newswires Live

PYC Therapeutics Ltd-grant of Patents by the US Patent Office

THOMSON REUTERS

PYC Therapeutics Appoints Chief Financial Officer

PYC Therapeutics Names CFO

MT Newswires Live

PYC Therapeutics Ltd-appointment of Chief Financial Officer

THOMSON REUTERS

Pleasing Signs As A Number Of Insiders Buy PYC Therapeutics Stock

Simply Wall St.

PYC Therapeutics Ltd-Company Secretary Appointment/Resignation

THOMSON REUTERS

PYC Therapeutics Ltd-Change to CEO Remuneration

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/PYC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"PYC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PYC.AU\",,,,,undefined,":{"symbol":"PYC.AU","market":"AU","secType":"STK","nameCN":"PYC THERAPEUTICS LTD","latestPrice":2.25,"timestamp":1789539120000,"preClose":2.26,"halted":0,"volume":1772350,"delay":0,"changeRate":-0.004424778761061853,"nameEN":"PYC THERAPEUTICS LTD","floatShares":348081085,"shares":983260447,"eps":-0.0591,"marketStatus":"Not Yet Opened","change":-0.01,"latestTime":"09-16 16:12:00 AEST","open":2.34,"high":2.35,"low":2.23,"amount":4011448,"amplitude":0.053097,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0591,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":2.26,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":0.5147246955401787,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PYC.AU","preClose":2.25,"auctionPrice":2.24,"auctionVolume":1296,"auctionTime":1789600069273,"referenceTime":1789554603098,"auction":1,"marketStatus":"盘前竞价","timestamp":1789600069273}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PYC.AU\",,,,,undefined,":{"symbol":"PYC.AU","floatShares":348081085,"roa":"-8.05%","roe":"-10.14%","lyrEps":-0.0591,"volumeRatio":0.5147246955401787,"shares":983260447,"dividePrice":0,"high":2.35,"amplitude":0.053097,"preClose":2.26,"low":2.23,"week52Low":0.865,"pbRate":"3.19","psRate":"85.11","week52High":2.62,"institutionHeld":0,"latestPrice":2.25,"eps":-0.0591,"divideRate":0,"volume":1772350,"delay":0,"ttmEps":-0.0591,"open":2.34,"prevYearClose":1.655,"prevWeekClose":2.3,"prevMonthClose":2.32,"prevQuarterClose":1.685,"fiveDayClose":2.42,"twentyDayClose":2.15,"sixtyDayClose":1.54,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PYC.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-11-15","symbol":"PYC.AU","defaultRemindTime":1731625200000,"type":"split","dateTimestamp":1731589200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"AU","date":"2024-03-18","symbol":"PYC.AU","defaultRemindTime":1710716400000,"type":"split","dateTimestamp":1710680400000,"forFactor":988235,"toFactor":1000000,"ratio":0.988235}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PYC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PYC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666511339","title":"PYC Therapeutics Says First Patient Dosed in Open-Label Extension of Drug Candidate Study in Polycystic Kidney Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2666511339","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666511339?lang=en_us&edition=fundamental","pubTime":"2026-09-11 07:28","pubTimestamp":1789082915,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  said the first patient was dosed in the Part D open-label extension of the ongoing multiple-ascending dose study of its PYC-003 drug candidate in polycystic kidney disease patients, according to a Friday Australian bourse filing.This patient has been receiving the drug candidate for a period of four months and will continue to receive PYC-003 every six weeks for up to 24 months.The objective of the ongoing study is to determine the safety and tolerability profile and optimal dosing regimen of the drug candidate in a repeat-dose setting before a proposed transition to a registrational trial.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PYC.AU","BK4139","BK4007","BK7067","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664033823","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2664033823","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664033823?lang=en_us&edition=fundamental","pubTime":"2026-09-03 11:14","pubTimestamp":1788405296,"startTime":"0","endTime":"0","summary":"Here are the ASX-listed companies with the biggest gains on Thursday.Southgold 2 : +8%, AU$12.27Phylogica : +7%, AU$2.61OrezOne : +6%, AU$2.75Block : +5%, AU$113.81Telix Pharmaceuticals : +5%, AU$16.44Kingsgate Consolidated : +4%, AU$5.39Deep Yellow : +4%, AU$1.61Resolute Mining : +4%, AU$1.44Perseus Mining : +4%, AU$6.66Life360 : +4%, AU$19.92","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRU.AU","PYC.AU","KCN.AU","SX2.AU","BK7067","TLX.AU","XYZ.AU","BK7506","BK7083","360.AU","BK7158","TLX","ORE.AU","BK7104","RSG.AU","BK7016","BK4139","DYL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881204","title":"Why PYC Therapeutics (ASX:PYC) Is Up 10.5% After Narrowing Its Full-Year Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881204","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881204?lang=en_us&edition=fundamental","pubTime":"2026-09-01 05:15","pubTimestamp":1788210928,"startTime":"0","endTime":"0","summary":"PYC Therapeutics Limited recently reported full-year results for the period ended June 30, 2026, with revenue rising to A$39.68 million from A$26.17 million and its net loss narrowing to A$43.34 million compared with A$50.3 million a year earlier.\nThe improvement in both top-line revenue and loss per share suggests the business is scaling its operations while gradually reducing the financial burden on shareholders.\nWe will now examine how this combination of higher revenue and a smaller...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/why-pyc-therapeutics-asxpyc-is-up-105-after-narrowing-its-fu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/why-pyc-therapeutics-asxpyc-is-up-105-after-narrowing-its-fu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","PYC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663010707","title":"PYC Therapeutics (ASX:PYC) Shares Chase Revenue Growth Despite Deep Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2663010707","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663010707?lang=en_us&edition=fundamental","pubTime":"2026-08-30 04:19","pubTimestamp":1788034748,"startTime":"0","endTime":"0","summary":"PYC Therapeutics stock closed at A$2.25 on Friday after a strong run over the past month, yet the fresh numbers still tell a story of a biotech deep in investment mode rather than profit harvest. The headline is the loss from continuing operations of A$43.8 million over the trailing twelve months, set against revenue of A$39.7 million. For long term holders, the bigger question now is how to weigh that loss profile against a P/B of 3.2x, which sits below both direct peers and the broader...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pyc-therapeutics-asxpyc-shares-chase-revenue-growth-despite","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pyc-therapeutics-asxpyc-shares-chase-revenue-growth-despite","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PYC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657418693","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2657418693","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657418693?lang=en_us&edition=fundamental","pubTime":"2026-08-07 11:25","pubTimestamp":1786073116,"startTime":"0","endTime":"0","summary":"Here are the ASX-listed companies with the biggest losses on Friday.4DMedical : -8%, AU$4.25ResMed : -6%, AU$29.55EchoIQ : -6%, AU$1.46Phylogica : -5%, AU$2.02DroneShield : -5%, AU$2.16EQ Resources : -5%, AU$0.31Block: -4%, AU$113.35Zip : -4%, AU$2.84Brazilian Rare Earths : -4%, AU$4.30Macmahon Holdings : -3%, AU$1.00","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7016","MAH.AU","BK7094","BRE.AU","BK7095","XYZ.AU","EIQ.AU","BK7158","BK7007","4DX.AU","ZIP.AU","BK7115","RMD.AU","BK7067","BK7501","EQR.AU","BK7093","DRO.AU","PYC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656899965","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2656899965","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656899965?lang=en_us&edition=fundamental","pubTime":"2026-08-04 10:59","pubTimestamp":1785812397,"startTime":"0","endTime":"0","summary":"Here are the ASX-listed companies with the biggest gains on Tuesday.DroneShield (ASX:DRO): +12%, AU$2.03MAAS Group Holdings (ASX:MGH): +11%, AU$5.52Almonty Industries CDI 1:1 (ASX:AII): +10%, AU$17.71","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7165","360.AU","BK7010","AII.AU","EQR.AU","BK7055","MGH.AU","PYC.AU","CQE.AU","BK7043","BK7095","BK7503","BK7067","DRO.AU","BNZ.AU","BK7115","MP1.AU","EOS.AU","BK7016"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655585889","title":"PYC Therapeutics Secures Approval for Higher Dosage in Phase 1b Multiple Ascending Dose Study in Polycystic Kidney Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2655585889","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655585889?lang=en_us&edition=fundamental","pubTime":"2026-07-29 11:20","pubTimestamp":1785295208,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  said it received Safety Review Committee approval in July to escalate dosing in the phase 1b part C multiple ascending dose study in polycystic kidney disease patients to the higher dose group of 2.4 milligrams per kilogram of its drug candidate PYC-003, according to a Wednesday Australian bourse filing.The company said it also received approval for an open-label extension of the ongoing study to enable continuous dosing of the drug candidate for a period of up to 24 months.It had AU$669 million of cash on hand as of June 30, per the filing.PYC Therapeutics' shares rose nearly 2% in recent trading on Wednesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LENZ","PYC.AU","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653241413","title":"PYC Therapeutics Says ADOA Patients Show Sustained Visual Acuity, Retinal Stress Improvements in Drug Candidate Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2653241413","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653241413?lang=en_us&edition=fundamental","pubTime":"2026-07-21 07:33","pubTimestamp":1784590408,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  said autosomal dominant optic atrophy  patients in the ongoing clinical trials of its PYC-001 drug candidate showed sustained improvement in both visual acuity and retinal stress following repeat doses, according to a Tuesday Australian bourse filing.Non-human primates treated with a single dose of the candidate at 15 micrograms per eye showed a sustained increase in OPA1 protein target gene expression in the retina four months after a single treatment.Human patients are currently receiving the candidate once every two to three months. The data from non-human primates support extending the dosing interval to once every four months or more. The firm plans to review the clinical protocol for the ongoing studies with a view to extending the dosing interval in these trials.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4096","BK4007","BK4539","LU0203345920.USD","LU0054578231.USD","PYC.AU","BK7067","BK4139","LENZ","AYI","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653924956","title":"What PYC Therapeutics (ASX:PYC)'s CFO Appointment of Biotech Finance Veteran Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2653924956","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653924956?lang=en_us&edition=fundamental","pubTime":"2026-07-21 05:22","pubTimestamp":1784582543,"startTime":"0","endTime":"0","summary":"PYC Therapeutics Limited recently appointed Thomas Ulmer as Chief Financial Officer, bringing 20 years of international leadership experience across biotechnology, pharmaceuticals and healthcare, including senior roles at Cell Therapies, PKG Health, Immatics N.V., Allergopharma and Merck Group.\nUlmer’s prior involvement in leading Immatics N.V. through a NASDAQ listing adds capital markets and listing experience that could be important for PYC Therapeutics’ future corporate and financing...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/what-pyc-therapeutics-asxpycs-cfo-appointment-of-biotech-fin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/what-pyc-therapeutics-asxpycs-cfo-appointment-of-biotech-fin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4585","XBI","BK4581","PYC.AU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650157502","title":"PYC Therapeutics (ASX:PYC) Names New CFO As Investors Weigh A Pricey Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2650157502","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650157502?lang=en_us&edition=fundamental","pubTime":"2026-07-12 07:20","pubTimestamp":1783812022,"startTime":"0","endTime":"0","summary":"PYC Therapeutics (ASX:PYC) drew investor attention after appointing Thomas Ulmer as Chief Financial Officer, adding biotechnology and pharmaceuticals finance experience that includes guiding Immatics N.V. through its listing as a US biotechnology company.\nSee our latest analysis for PYC Therapeutics.\nBeyond the CFO appointment, PYC Therapeutics has seen a 31.78% 1 month share price return and a 32.34% 3 month share price return, while its 3 year total shareholder return of 131.44% points to...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pyc-therapeutics-asxpyc-names-new-cfo-as-investors-weigh-a-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pyc-therapeutics-asxpyc-names-new-cfo-as-investors-weigh-a-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK7067","ISBC","PYC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650699084","title":"Will PYC Therapeutics’ New CFO Shift Its Capital-Market Ambitions Up a Gear (ASX:PYC)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2650699084","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650699084?lang=en_us&edition=fundamental","pubTime":"2026-07-09 00:22","pubTimestamp":1783527729,"startTime":"0","endTime":"0","summary":"PYC Therapeutics Limited recently appointed Mr. Thomas Ulmer as Chief Financial Officer, adding more than 20 years of international biotechnology, pharmaceutical and healthcare leadership to its executive team.\nUlmer’s prior experience guiding Immatics N.V. through its NASDAQ listing gives PYC access to finance leadership familiar with cross-border capital markets and public-company standards.\nWe’ll now examine how Ulmer’s international capital markets background, including NASDAQ listing...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/will-pyc-therapeutics-new-cfo-shift-its-capital-market-ambit","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/will-pyc-therapeutics-new-cfo-shift-its-capital-market-ambit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","PYC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649956190","title":"PYC Therapeutics Announces Grant of Patents by the US Patent Office","url":"https://stock-news.laohu8.com/highlight/detail?id=2649956190","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649956190?lang=en_us&edition=fundamental","pubTime":"2026-07-08 08:57","pubTimestamp":1783472245,"startTime":"0","endTime":"0","summary":"BRIEF-PYC Therapeutics Announces Grant Of Patents By The US Patent OfficeJuly 8 (Reuters)-PYC Therapeutics LtdPYC.AX:GRANT OF PATENTS BY THE US PATENT OFFICEANNOUNCES US PATENT OFFICE GRANTS PATENTS FOR ALL THREE CLINICAL-STAGE RNA DRUG CANDIDATESFurther company coverage:PYC.AX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nTUE4PWDQ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649955847","title":"PYC Therapeutics Says US Patent Office Grants Composition of Matter Patents for Three Drug Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2649955847","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649955847?lang=en_us&edition=fundamental","pubTime":"2026-07-08 07:44","pubTimestamp":1783467897,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  said the US Patent Office granted composition of matter patents covering three of its drug candidates and extended the patent life for PYC-003 through to June 13, 2044, for PYC-001 through to April 10, 2043, and for VP-001 through to May 17, 2043, according to a Wednesday Australian bourse filing.PYC-003 seeks to address the underlying cause of polycystic kidney disease, PYC-001 seeks to address autosomal dominant optic atrophy, and VP-001 seeks to address retinitis pigmentosa type 11, per the filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","PYC.AU","BK7067","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649953233","title":"PYC Therapeutics Ltd-grant of Patents by the US Patent Office","url":"https://stock-news.laohu8.com/highlight/detail?id=2649953233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649953233?lang=en_us&edition=fundamental","pubTime":"2026-07-08 07:01","pubTimestamp":1783465310,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUE4PWDQ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PYC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649460861","title":"PYC Therapeutics Appoints Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2649460861","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649460861?lang=en_us&edition=fundamental","pubTime":"2026-07-07 09:32","pubTimestamp":1783387934,"startTime":"0","endTime":"0","summary":"BRIEF-PYC Therapeutics Appoints Chief Financial OfficerJuly 7 (Reuters)-PYC Therapeutics LtdPYC.AX:APPOINTMENT OF CHIEF FINANCIAL OFFICERAPPOINTS THOMAS ULMER AS CHIEF FINANCIAL OFFICERFurther company coverage:PYC.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUE7MNHYW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649964672","title":"PYC Therapeutics Names CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2649964672","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649964672?lang=en_us&edition=fundamental","pubTime":"2026-07-07 07:07","pubTimestamp":1783379231,"startTime":"0","endTime":"0","summary":"PYC Therapeutics (ASX:PYC) appointed Thomas Ulmer as the company's chief financial officer, according to a Tuesday Australian bourse filing.Ulmer most recently served as the CFO of Cell Therapies.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","LENZ","BK7067","BK4139","PYC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649267478","title":"PYC Therapeutics Ltd-appointment of Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2649267478","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649267478?lang=en_us&edition=fundamental","pubTime":"2026-07-07 06:21","pubTimestamp":1783376482,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nTUE7MNHYW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PYC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645870041","title":"Pleasing Signs As A Number Of Insiders Buy PYC Therapeutics Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2645870041","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645870041?lang=en_us&edition=fundamental","pubTime":"2026-06-22 11:54","pubTimestamp":1782100459,"startTime":"0","endTime":"0","summary":"Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pleasing-signs-as-a-number-of-insiders-buy-pyc-therapeutics","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pleasing-signs-as-a-number-of-insiders-buy-pyc-therapeutics","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PYC.AU","BK7067","LENZ","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643222350","title":"PYC Therapeutics Ltd-Company Secretary Appointment/Resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2643222350","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643222350?lang=en_us&edition=fundamental","pubTime":"2026-06-15 13:01","pubTimestamp":1781499665,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUE3JYTMV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PYC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638590542","title":"PYC Therapeutics Ltd-Change to CEO Remuneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2638590542","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638590542?lang=en_us&edition=fundamental","pubTime":"2026-05-26 17:23","pubTimestamp":1779787406,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUE2TGGGY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PYC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}]}}